EP4555086A1 — Oligonucleotides for adar-mediated rna editing and use thereof
Assigned to ProQR Therapeutics II BV · Expires 2025-05-21 · 1y expired
What this patent protects
The invention relates to antisense oligonucleotides that can form a double stranded nucleic acid complex with a target RNA molecule, wherein the double stranded nucleic acid complex is capable of recruiting an adenosine deaminating enzyme for deamination of a target adenosine in …
USPTO Abstract
The invention relates to antisense oligonucleotides that can form a double stranded nucleic acid complex with a target RNA molecule, wherein the double stranded nucleic acid complex is capable of recruiting an adenosine deaminating enzyme for deamination of a target adenosine in the target RNA molecule, wherein the nucleotide directly 5' of the target adenosine in the target RNA molecule is a guanosine (5'-G), and wherein the nucleotide in the AON that is opposite the guanosine is a nucleotide analog that can induce a syn conformation of the guanosine.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.